BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26985855)

  • 1. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
    Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
    Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
    Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
    Pellicano F; Scott MT; Helgason GV; Hopcroft LE; Allan EK; Aspinall-O'Dea M; Copland M; Pierce A; Huntly BJ; Whetton AD; Holyoake TL
    Stem Cells; 2014 Sep; 32(9):2324-37. PubMed ID: 24806995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
    Borriello A; Caldarelli I; Bencivenga D; Cucciolla V; Oliva A; Usala E; Danise P; Ronzoni L; Perrotta S; Della Ragione F
    Carcinogenesis; 2011 Jan; 32(1):10-8. PubMed ID: 20952511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
    Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
    Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
    Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
    Agarwal P; Li H; Choi K; Hueneman K; He J; Welner RS; Starczynowski DT; Bhatia R
    Cell Rep; 2021 Jul; 36(2):109386. PubMed ID: 34260914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.
    Trinh A; Khamari R; Fovez Q; Mahon FX; Turcq B; Bouscary D; Maboudou P; Joncquel M; Coiteux V; Germain N; Laine W; Dekiouk S; Jean-Pierre S; Maguer-Satta V; Ghesquiere B; Idziorek T; Quesnel B; Kluza J; Marchetti P
    Mol Metab; 2022 Jan; 55():101410. PubMed ID: 34863941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
    PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
    Bono S; Dello Sbarba P; Lulli M
    Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.